Enanta, Novartis deal

Enanta said Novartis will return rights to the biotech's EDP-239, an HCV non-structural protein 5A (NS5A) inhibitor that is in Phase I testing, as the pharma exits the HCV business. Novartis acquired exclusive, worldwide rights to EDP-239 in February 2012. Enanta received $34 million up front and an $11 million milestone payment in January 2013 triggered by Novartis starting dosing in the first Phase I trial of EDP-239 (see BioCentury, Feb. 27, 2012). ...